In this presentation from the Cardiomyopathy UK National Conference 2023, Perry Elliott, Professor in Inherited Cardiovascular Disease at University College London explores what the future might look like for cardiomyopathy care. Libby Jarman, Trustee of Cardiomyopathy UK joins Professor Elliott in discussion, followed by audience questions.
Perry Elliott - Presentation
00:01:39 – What is personalised medicine?
00:04:27 – What does ‘aetiology’ mean?
00:05:20 – Defining cardiomyopathy
00:05:48 – The genetic architecture of cardiomyopathy
00:07:37 – ESC cardiovascular disease statistics
00:08:33 – Case study 1
00:11:37 – Case study 2
00:14:16 – Genotype-phenotype correlations
00:15:51 – Drugs that can treat the underlying cause – the case of Transthyretin Amyloidosis (ATTR)
00:16:56 – Mavacamten for the treatment of hypertrophic obstructive cardiomyopathy (HoCM)
00:17:23 – Modifying abnormal genes
00:18:35 – Frontiers: New Armoury
Perry Elliott and Libby Jarman in conversation
00:19:56 – How close are we to accessing Mavacamten on the NHS?
00:23:58 – Is Mavacamten effective in non-obstructive hypertrophic cardiomyopathy?
00:25:45 – When will Tafamidis be available on the NHS?
00:27:46 – Is there a risk that precision medicine will miss some specific types of disease?
00:32:00 – How many non-cardiomyopathy-specialist cardiologists ‘go the extra mile’ to define cardiomyopathy?
00:35:00 – Are we moving beyond basic descriptions of cardiomyopathy towards the MOGE(S) classification? [ Ссылка ]
Audience questions
00:40:10 – How can patients help with personalised medicine?
00:42:15 – Can stem cells be used to repair heart muscle?
00:44:15 – How does Mavacamten work?
00:46:20 – How will patients be prioritised for Mavacamten and similar drugs?
00:48:00 – Should treatment be personalised based on gene, age, gender, or other factors?
00:49:30 – How will the NHS manage these new treatments in the future?
00:53:33 – How can we influence change in the healthcare system?
00:56:30 – Who owns medical data that comes from cardiac devices?
01:00:08 – What impact does a polygenic disease aetiology mean when it comes to the efficacy of personalised medicine?
01:02:35 – What impact do comorbidities have on cardiomyopathy treatment?
01:04:30 – My experience of managing comorbidities
Find out more at www.cardiomyopathy.org
#cardiomyopathy #heartmuscledisease #pacemaker #ICD #CRT #S-ICD #defibrillator #ILR #cardiomyopathyawareness #cardiacrehab #cardiacrehabilitation #CardioConference #mavacamten #MRI #Echo #CMRi #ACM #HCM #DCM #ESC #PPCM #Takotsubo
